Open Access

Association of obstructive sleep apnea/hypopnea syndrome with glaucomatous optic neuropathy and ocular blood flow

  • Authors:
    • Georgios Dalianis
    • Alexandra Trivli
    • Aliki Limnopoulou
    • Andreas Stavrakis
    • Chryssa Terzidou
    • Efstathios T. Detorakis
    • Vassilios Kozobolis
    • Georgios Labiris
  • View Affiliations

  • Published online on: April 20, 2021     https://doi.org/10.3892/etm.2021.10089
  • Article Number: 657
  • Copyright: © Dalianis et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study aimed to investigate the prevalence of glaucomatous optic neuropathy in patients with obstructive sleep apnea/hypopnea syndrome (OSAHS). In total, 83 subjects (45 cases of severe OSAHS and 38 controls) underwent polysomnographic assessment and were evaluated for the severity of the disease using the Apnea‑Hypopnea index. A detailed ophthalmologic exam was then performed, including measurement of the intraocular pressure (IOP) with a Goldmann applanation tonometer and Pascal dynamic contour tonometer (DCT), recording of the ocular pulse amplitude measured by the Pascal DCT, standard automated perimetry and retinal nerve fiber layer (RNFL) and ganglion cell complex (GCC) thickness evaluation using optical coherence tomography. Ocular blood flow was assessed using color Doppler imaging (CDI) and ophthalmic artery indices were evaluated, including peak systolic blood velocity, end diastolic blood velocity and resistivity index (RI). There was a significant difference in the mean IOP between controls (11.03±3.85 mmHg) and cases of severe OSAHS (18.06±3.39 mmHg) when the IOP was measured by DCT (P<0.0001), but not with the Goldmann applanation tonometer (IOP, 13.97±2.85 mmHg for controls and 14.89±3.21 mmHg for cases of severe OSAHS; P=0.0877). Significant negative correlations were observed between RNFL thickness and RI (P=0.0011) in cases of severe OSAHS, as well as between GCC thickness and RI (P<0.008) in all subjects. Furthermore, a negative correlation between RI and RNFL thickness in severe cases of OSAHS suggested a hemodynamically induced vulnerability of RNFL in OSAHS. The correlation between RI and GCC thickness in all subjects suggested that impaired perfusion, more prominent in OSAHS, leads to structural changes. Therefore, cases of severe OSAHS should be monitored for changes in RNFL and GCC thickness, as well as CDI findings. Furthermore, patients with increased ophthalmic artery RIs should be monitored for changes in the GCC, regardless of the etiology of the RI increase.

Related Articles

Journal Cover

June-2021
Volume 21 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Dalianis G, Trivli A, Limnopoulou A, Stavrakis A, Terzidou C, Detorakis ET, Kozobolis V and Labiris G: Association of obstructive sleep apnea/hypopnea syndrome with glaucomatous optic neuropathy and ocular blood flow. Exp Ther Med 21: 657, 2021
APA
Dalianis, G., Trivli, A., Limnopoulou, A., Stavrakis, A., Terzidou, C., Detorakis, E.T. ... Labiris, G. (2021). Association of obstructive sleep apnea/hypopnea syndrome with glaucomatous optic neuropathy and ocular blood flow. Experimental and Therapeutic Medicine, 21, 657. https://doi.org/10.3892/etm.2021.10089
MLA
Dalianis, G., Trivli, A., Limnopoulou, A., Stavrakis, A., Terzidou, C., Detorakis, E. T., Kozobolis, V., Labiris, G."Association of obstructive sleep apnea/hypopnea syndrome with glaucomatous optic neuropathy and ocular blood flow". Experimental and Therapeutic Medicine 21.6 (2021): 657.
Chicago
Dalianis, G., Trivli, A., Limnopoulou, A., Stavrakis, A., Terzidou, C., Detorakis, E. T., Kozobolis, V., Labiris, G."Association of obstructive sleep apnea/hypopnea syndrome with glaucomatous optic neuropathy and ocular blood flow". Experimental and Therapeutic Medicine 21, no. 6 (2021): 657. https://doi.org/10.3892/etm.2021.10089